CAS: 1369761-01-2

Cerdulatinib is a small molecule that inhibits the activity of the IL-2 receptor. It has been shown to be active against t-cell lymphomas and other cancers such as prostate cancer, breast cancer, and lung cancer. Cerdulatinib inhibits the transcriptional activation of survivin, an anti-apoptotic protein, which may lead to cell death in some cancers. The mechanism of action of cerdulatinib is not well understood, but it has been shown to inhibit nuclear DNA synthesis by binding to nuclear dna and inhibiting cell lysis. Cerdulatinib also has structural similarities with cyclosporine A (CsA), a drug used for transplant rejection. This drug is being studied as a possible treatment for humans with hematopoietic diseases or organ transplant rejection.br>br>

4-(Cyclopropylamino)-2-((4-(4-(Ethylsulfonyl)Piperazin-1-Yl)Phenyl)Amino)Pyrimidine-5-Carboxamide Hydrochloride

Cerdulatinib hydrochloride

Cerdulatinib hydrochloride is an oral tyrosine kinase inhibitor targeting JAK1/2/3, TYK2, Syk, and 19 others with IC50 < 200 nM.